Page last updated: 2024-08-21

pyrazines and Cancer of Pancreas

pyrazines has been researched along with Cancer of Pancreas in 58 studies

Research

Studies (58)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (5.17)18.2507
2000's24 (41.38)29.6817
2010's24 (41.38)24.3611
2020's7 (12.07)2.80

Authors

AuthorsStudies
Abdelsalam, M; Hastreiter, S; Ibrahim, HS; Krauss, L; Schneider, G; Schutkowski, M; Sippl, W; Vecchio, A; Zessin, M1
Hamamoto, T; Hirohara, M; Masuda, Y; Morimoto, Y; Takada, K; Takagi, A; Takeuchi, O; Watanabe, K1
de Assuncao, TM; Dusetti, N; Iovanna, J; Lomberk, G; Mathison, A; Salmonson, A; Toro-Zapata, J; Urrutia, G; Urrutia, R1
Benson, AB; Davis, RE; Javle, M; Kumar-Sinha, C; Lopez, CD; Maitra, A; Mettu, NB; Munugalavadla, V; Neelapu, S; Overman, M; Parra, ER; Patel, P; Tao, L; Vats, P; Xiao, L1
Bai, M; Che, X; Jing, W; Li, C; Li, Z; Liu, Y; Qu, X; Song, N; Teng, Z1
Brekken, RA; Hosein, AN; Maitra, A1
Hamamoto, T; Hirohara, M; Masuda, Y; Morimoto, Y; Takada, K; Takeuchi, O; Watanabe, K1
Anthony, LB; Carreira, VS; Chu, Z; Dahche, HM; Jiang, M; Koch, SE; Komurov, K; LaSance, K; Mercer, CA; Orr-Asman, MA; Plas, DR; Qi, X; Rubinstein, J; Thomas, HE; Worley, M1
Batra, SK; Dhanasingh, I; Kanteti, R; Kaushik, G; Kindler, HL; Kulkarni, P; Mambetsariev, B; Mirzapoiazova, T; Nasser, MW; Ponnusamy, MP; Riehm, JJ; Salgia, R; Seshacharyulu, P; Wang, J1
Christensen, JG; Ishiguro-Oonuma, T; McDonald, DM; Schriver, BJ; Sennino, B1
Aston-Mourney, K; Goldstein, LC; Hull, RL; Meier, DT; Samarasekera, T; Subramanian, SL; Zraika, S1
Carew, JS; Coffey, M; Espitia, CM; Freeman, JW; Kelly, KR; Nawrocki, ST; Zhao, W1
Almeida, GM; Coelho, MA; Coelho, SC; Juzenas, P; Pereira, MC; Rocha, S; Sampaio, P; Silva, FS1
Cheng, B; Gong, L; Jing, Y; Tang, X; Wu, GJ; Xu, M; Yang, B; Zheng, P1
Abujamra, AL; Alemar, B; Ashton-Prolla, P; de Farias, CB; Giacomazzi, J; Hainaut, P; Hautefeuille, A; Izetti, P; Lenz, G; Osvaldt, AB; Roesler, R; Schwartsmann, G1
Chen, ZR; Huang, M; Min, H; Xu, M; Zheng, K; Zhou, JD; Zou, XP1
Chien, W; Ding, LW; Garg, M; Gery, S; Kitajima, S; Koeffler, PH; Lee, KL; Leong, WZ; Lim, SL; Poellinger, L; Sun, H; Sun, QY; Takao, S; Tan, SZ; Tokatly, I; Torres-Fernandez, LA; Xiao, J1
Almeida, GM; Coelho, MA; Frasco, MF; Pereira, Mdo C; Santos-Silva, F1
François, RA; Hochwald, SN; Kaye, FJ; Maeng, K; Nawab, A; Zajac-Kaye, M1
Barda, D; Barnard, D; Beckmann, R; Burke, T; Diaz, HB; Donoho, G; Jones, B; King, C; Marshall, M1
Cusack, JC; Houston, M; Liu, R; Ljungman, D; Palladino, MA; Sloss, CM; Wang, F; Xia, L1
Märten, A; Mehrle, S; Schmidt, J; Serba, S; von Lilienfeld-Toal, M; Zeiss, N1
Chen, Q; Hunsucker, SA; Kuhn, DJ; Orlowski, M; Orlowski, RZ; Voorhees, PM1
Chim, CS; Hwang, YY; Pang, C; Shek, TW1
Jin, J; Liu, H; Tong, HY; Wei, JY; Yu, WJ; Zhang, FJ; Zhu, WF1
Granberg, D; Hassan, S; Larsson, DE; Oberg, K; Wickström, M1
Butler, PC; Elashoff, M; Elashoff, R; Gier, B; Matveyenko, AV1
Jeong, KS; Kim, YT; Lee, JK; Lee, SH; Park, JK; Ryu, JK; Woo, SM; Yang, KY; Yoon, WJ; Yoon, YB1
Eckhardt, SG; Kulikowski, GN; Morelli, MP; Pitts, TM; Serkova, NJ; Spratlin, JL; Tentler, JJ1
Gundert-Remy, U; Spranger, J; Stammschulte, T1
Niessen, M; Spinas, GA; Xu, L1
Hahn, EG; Kalden, JR; Meister, S; Ocker, M; Voll, R; Wissniowski, TT1
Cao, Q; Dudek, AZ; Wang, H1
Brunner, TB; Charlton, PA; Fokas, E; McKenna, WG; Muschel, RJ; Pollard, JR; Prevo, R; Reaper, PM1
Brunner, TB; Charlton, PA; Cornelissen, B; Fokas, E; Gillies McKenna, W; Hammond, EM; Muschel, RJ; Olcina, MM; Pollard, JR; Prevo, R; Reaper, PM; Vallis, KA1
Abbruzzese, JL; Chiao, PJ; Dong, QG; Evans, DB; Fujioka, S; McDonnell, TJ; Peng, B; Schmidt, C; Sclabas, GM; Tsao, MS; Wu, T1
Abbruzzese, JL; Baker, C; Chiao, PJ; Dong, QG; Evans, DB; Frederick, WA; Fujioka, S; Schmidt, C; Sclabas, GM1
Bold, RJ; Fahy, BN; Schlieman, MG; Virudachalam, S1
McConkey, DJ; Nawrocki, ST; Sweeney-Gotsch, B; Takamori, R1
Grever, M; Kindler, HL; Kleiber, B; Shah, MH; Webb, I; Wright, J; Young, D1
Callery, MP; Canete, JJ; Chandler, NM1
Alberts, SR; Block, M; Burch, P; Foster, N; Jatoi, A; Kugler, J; Morton, R; Nguyen, PL1
Bai, J; Callery, MP; Demirjian, A; Marasco, W; Sui, J; Vollmer, CM1
Bold, RJ; Fahy, BN; Mortenson, MM; Schlieman, MG; Virudachalam, S1
Alberts, SR; Fitch, TR; Foster, NR; Gill, S; Kim, GP; Kugler, J; Morton, RF; Schaefer, P; Steen, P; Wiesenfeld, M1
Abbruzzese, JL; Boise, LH; Carew, JS; Chiao, PJ; Dunner, K; Huang, P; McConkey, DJ; Nawrocki, ST1
Abbruzzese, JL; Carew, JS; Dunner, K; Highshaw, RA; Huang, P; McConkey, DJ; Nawrocki, ST; Pino, MS1
Huang, DC; Sinicrope, FA; Yeung, BH1
Abbruzzese, JL; Andtbacka, RH; Bornmann, WG; Carew, JS; Chiao, PJ; Dunner, K; Highshaw, RA; Huang, P; McConkey, DJ; Nawrocki, ST; Pal, A; Pino, MS; Xiong, H1
Hughes, M; Micallef-Eynaud, P1
Bai, J; Callery, MP; Demirjian, A; Marasco, W; Sui, J1
Abbruzzese, JL; Andtbacka, R; Arumugam, T; Khanbolooki, S; Kurzrock, R; Logsdon, CD; McConkey, DJ; Nawrocki, ST; Pino, MS1
Gao, SL; Shen, HW; Tang, ZY; Wu, YL1
Clapper, ML; Lang, D; Leahy, K; Miknyoczki, S; Ruggeri, BA; Wood, M1
Bolli, GB; Brunetti, P; Ciofetta, M; Di Vincenzo, A; Epifano, L; Fanelli, C; Lepore, M; Modarelli, F; Pampanelli, S1
Hirahara, N; Minari, Y; Nio, Y; Ohmori, H; Sasaki, S; Takamura, M; Tamura, K1
Bold, RJ; McConkey, DJ; Virudachalam, S1

Reviews

1 review(s) available for pyrazines and Cancer of Pancreas

ArticleYear
Pancreatic cancer stroma: an update on therapeutic targeting strategies.
    Nature reviews. Gastroenterology & hepatology, 2020, Volume: 17, Issue:8

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Extracellular Fluid; Extracellular Matrix; Focal Adhesion Protein-Tyrosine Kinases; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Mice; Molecular Targeted Therapy; Pancreatic Neoplasms; Permeability; Pressure; Protein Kinase Inhibitors; Pyrazines; rho-Associated Kinases; Sulfonamides; Tumor Microenvironment

2020

Trials

4 trial(s) available for pyrazines and Cancer of Pancreas

ArticleYear
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.
    Journal for immunotherapy of cancer, 2020, Volume: 8, Issue:1

    Topics: Administration, Intravenous; Administration, Oral; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Pancreatic Ductal; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Myeloid-Derived Suppressor Cells; Pancreatic Neoplasms; Programmed Cell Death 1 Receptor; Progression-Free Survival; Proof of Concept Study; Pyrazines; Tumor Microenvironment

2020
Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy.
    Anticancer research, 2012, Volume: 32, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Male; Middle Aged; Pancreatic Neoplasms; Panobinostat; Pyrazines

2012
Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-15, Volume: 10, Issue:18 Pt 1

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carcinoid Tumor; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Time Factors; Treatment Outcome

2004
PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrazines; Survival Analysis; Treatment Outcome

2005

Other Studies

53 other study(ies) available for pyrazines and Cancer of Pancreas

ArticleYear
Development of Pyrazine-Anilinobenzamides as Histone Deacetylase HDAC1-3 Selective Inhibitors and Biological Testing Against Pancreas Cancer Cell Lines.
    Methods in molecular biology (Clifton, N.J.), 2023, Volume: 2589

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Pancreatic Neoplasms; Protein Isoforms; Pyrazines; Structure-Activity Relationship

2023
Prexasertib increases the sensitivity of pancreatic cancer cells to gemcitabine and S‑1.
    Oncology reports, 2020, Volume: 43, Issue:2

    Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Down-Regulation; Drug Combinations; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Oxonic Acid; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrazoles; Tegafur

2020
Combined Targeting of G9a and Checkpoint Kinase 1 Synergistically Inhibits Pancreatic Cancer Cell Growth by Replication Fork Collapse.
    Molecular cancer research : MCR, 2020, Volume: 18, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzimidazoles; Carcinoma, Pancreatic Ductal; Checkpoint Kinase 1; DNA Replication; Drug Synergism; Enzyme Inhibitors; Female; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Mice; Mice, Nude; Molecular Targeted Therapy; Pancreatic Neoplasms; Pyrazines; Pyrazoles; Random Allocation; Xenograft Model Antitumor Assays

2020
PD-L1 upregulation accompanied with epithelial-mesenchymal transition attenuates sensitivity to ATR inhibition in p53 mutant pancreatic cancer cells.
    Medical oncology (Northwood, London, England), 2020, Apr-10, Volume: 37, Issue:5

    Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; B7-H1 Antigen; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Knockdown Techniques; Humans; Hyaluronan Receptors; Pancreatic Neoplasms; Pyrazines; Sulfones; Tumor Suppressor Protein p53; Up-Regulation

2020
Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2.
    Molecular and cellular biochemistry, 2020, Volume: 472, Issue:1-2

    Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrazoles; Sulfonamides; Tumor Cells, Cultured

2020
mTOR Kinase Inhibition Effectively Decreases Progression of a Subset of Neuroendocrine Tumors that Progress on Rapalog Therapy and Delays Cardiac Impairment.
    Molecular cancer therapeutics, 2017, Volume: 16, Issue:11

    Topics: Animals; Carcinoid Heart Disease; Cell Line, Tumor; Drug Resistance, Neoplasm; Everolimus; Gene Expression Regulation, Neoplastic; Humans; Mice; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrazines; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2017
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
    Cancer biology & therapy, 2018, 04-03, Volume: 19, Issue:4

    Topics: Animals; Benzamides; Carcinoma, Pancreatic Ductal; Cell Adhesion; Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Focal Adhesion Kinase 1; Focal Adhesion Kinase 2; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Transgenic; Neoplasms, Experimental; Pancreatic Neoplasms; Phosphorylation; Pleural Neoplasms; Proto-Oncogene Proteins p21(ras); Pyrazines; Quinolones; Sulfonamides; Sulfones

2018
Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice.
    Cancer research, 2013, Jun-15, Volume: 73, Issue:12

    Topics: Animals; Antibodies; Antineoplastic Agents; Gene Expression Regulation, Neoplastic; Immunohistochemistry; Indoles; Lymphatic Metastasis; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microscopy, Confocal; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-met; Pyrazines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sunitinib; Triazoles; Vascular Endothelial Growth Factor C

2013
One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.
    American journal of physiology. Endocrinology and metabolism, 2013, Aug-15, Volume: 305, Issue:4

    Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Hemizygote; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Islet Amyloid Polypeptide; Male; Metformin; Mice; Mice, Transgenic; Pancreas; Pancreatic Neoplasms; Pancreatitis; Plaque, Amyloid; Pyrazines; Random Allocation; Recombinant Proteins; Sitagliptin Phosphate; Time Factors; Triazoles

2013
Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer.
    Cell death & disease, 2013, Jul-18, Volume: 4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Brefeldin A; Caspases, Initiator; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Endoplasmic Reticulum Stress; Epithelial Cells; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Oncolytic Virotherapy; Oncolytic Viruses; Orthoreovirus, Mammalian; Pancreas; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; ras Proteins; Reoviridae; Tunicamycin; Virus Replication; Xenograft Model Antitumor Assays

2013
Gold nanoparticle delivery-enhanced proteasome inhibitor effect in adenocarcinoma cells.
    Expert opinion on drug delivery, 2013, Volume: 10, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Synergism; Epithelial Cells; Gold; Humans; Nanoparticles; Pancreatic Ducts; Pancreatic Neoplasms; Polyethylene Glycols; Proteasome Inhibitors; Pyrazines; Tumor Cells, Cultured

2013
Bortezomib-induced apoptosis in cultured pancreatic cancer cells is associated with ceramide production.
    Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Ceramides; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase Kinase 5; Morpholines; Pancreatic Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Pyrazines

2014
PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
    Investigational new drugs, 2014, Volume: 32, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Aza Compounds; Boronic Acids; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Imidazoles; Mutation; Pancreatic Neoplasms; Piperazines; Pyrazines; Quinazolines; RNA, Small Interfering; Tumor Suppressor Protein p53

2014
Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:1

    Topics: Adenine; AMP-Activated Protein Kinases; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezomib; Cell Survival; Cells, Cultured; Chloroquine; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Neoplasm Proteins; Pancreatic Neoplasms; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; RNA Interference; RNA, Small Interfering

2014
Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells.
    Oncotarget, 2014, Jul-15, Volume: 5, Issue:13

    Topics: Animals; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Drug Synergism; Endoribonucleases; Enzyme Inhibitors; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred NOD; Mice, SCID; Naphthalenes; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Pyrazines; Regulatory Factor X Transcription Factors; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA Splicing; Sulfonamides; Thiophenes; Toyocamycin; Transcription Factors; Unfolded Protein Response; X-Box Binding Protein 1; Xenograft Model Antitumor Assays

2014
Transferrin surface-modified PLGA nanoparticles-mediated delivery of a proteasome inhibitor to human pancreatic cancer cells.
    Journal of biomedical materials research. Part A, 2015, Volume: 103, Issue:4

    Topics: Boronic Acids; Bortezomib; Cell Death; Cell Line, Tumor; Endocytosis; Humans; Lactic Acid; Nanoparticles; Pancreatic Neoplasms; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Proteasome Inhibitors; Pyrazines; Spectroscopy, Fourier Transform Infrared; Telomerase; Transferrin

2015
Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
    Journal of the National Cancer Institute, 2015, Volume: 107, Issue:8

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Female; Focal Adhesion Kinase 1; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neuroendocrine Tumors; Organic Chemicals; Pancreatic Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Pyrazines; Signal Transduction; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays

2015
LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.
    Investigational new drugs, 2016, Volume: 34, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Colonic Neoplasms; Deoxycytidine; DNA Damage; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Xenograft Model Antitumor Assays

2016
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Aug-15, Volume: 14, Issue:16

    Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lactones; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrroles; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays

2008
Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:11

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrazines; RGS Proteins; Vascular Endothelial Growth Factor A

2008
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.
    Blood, 2009, May-07, Volume: 113, Issue:19

    Topics: Anti-Inflammatory Agents; Apoptosis; Binding, Competitive; Boronic Acids; Bortezomib; Cells, Cultured; Chromosome Deletion; Chromosomes, Human, Pair 13; Dexamethasone; Dipeptides; Drug Resistance, Neoplasm; Drug Synergism; Endothelium, Vascular; Humans; Immunoblotting; Multiple Myeloma; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Umbilical Veins

2009
Restoration of chemosensitivity by bortezomib: implications for refractory myeloma.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:4

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Multiple Myeloma; Pancreatic Neoplasms; Pleural Neoplasms; Protease Inhibitors; Pyrazines; Treatment Outcome

2009
Bortezomib in treatment of extramedullary plasmacytoma of the pancreas.
    Hepatobiliary & pancreatic diseases international : HBPD INT, 2009, Volume: 8, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Middle Aged; Pancreatic Neoplasms; Plasmacytoma; Pyrazines; Retreatment; Treatment Outcome; Vincristine

2009
The cytotoxic agents NSC-95397, brefeldin A, bortezomib and sanguinarine induce apoptosis in neuroendocrine tumors in vitro.
    Anticancer research, 2010, Volume: 30, Issue:1

    Topics: Apoptosis; Benzophenanthridines; Boronic Acids; Bortezomib; Brefeldin A; Carcinoid Tumor; Carcinoma, Bronchogenic; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Lung Neoplasms; Naphthoquinones; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrazines

2010
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
    Gastroenterology, 2011, Volume: 141, Issue:1

    Topics: Adverse Drug Reaction Reporting Systems; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Odds Ratio; Pancreatic Neoplasms; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Thyroid Neoplasms; Triazoles; United States; United States Food and Drug Administration; Venoms

2011
Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.
    Pancreas, 2011, Volume: 40, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Vorinostat; Xenograft Model Antitumor Assays

2011
Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.
    Anticancer research, 2011, Volume: 31, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunoblotting; Liver Neoplasms; Magnetic Resonance Spectroscopy; Metabolomics; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Sulfonamides

2011
GLP-1-based therapies: the dilemma of uncertainty.
    Gastroenterology, 2011, Volume: 141, Issue:1

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Pancreatic Neoplasms; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Risk Assessment; Risk Factors; Sitagliptin Phosphate; Thyroid Neoplasms; Triazoles; Uncertainty; Venoms

2011
Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4?
    Gastroenterology, 2011, Volume: 141, Issue:6

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Pancreatic Neoplasms; Pancreatitis; Peptides; Pyrazines; Receptors, Glucagon; Thyroid Neoplasms; Triazoles; Venoms

2011
Exenatide and sitagliptin: pancreatitis and pancreatic cancer. Harms on the rise.
    Prescrire international, 2011, Volume: 20, Issue:121

    Topics: Exenatide; Humans; Hypoglycemic Agents; Pancreatic Neoplasms; Pancreatitis; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms

2011
Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
    International journal of oncology, 2012, Volume: 40, Issue:5

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Pancreatic Ductal; Caspase 12; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Electrophoretic Mobility Shift Assay; Endoplasmic Reticulum; Flow Cytometry; Gemcitabine; Humans; In Situ Nick-End Labeling; Membrane Potential, Mitochondrial; Mitochondria; Mucins; NF-kappa B; Pancreatic Neoplasms; Polymerase Chain Reaction; Protease Inhibitors; Pyrazines; Regulatory Factor X Transcription Factors; RNA Interference; Time Factors; Transcription Factor CHOP; Transcription Factors; Transfection; Unfolded Protein Response; X-Box Binding Protein 1

2012
The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.
    Cancer biology & therapy, 2012, Volume: 13, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Hypoxia; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; DNA Damage; DNA Repair; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Pyrazines; Radiation-Sensitizing Agents; Signal Transduction; Sulfones

2012
Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.
    Cell death & disease, 2012, Dec-06, Volume: 3

    Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; DNA Damage; Female; Humans; Isoxazoles; Mice; Mice, Inbred BALB C; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Pyrazines; Radiation Tolerance; Radiation-Sensitizing Agents

2012
The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis.
    Oncogene, 2002, Sep-19, Volume: 21, Issue:42

    Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Cell Differentiation; Cell Division; Chloramphenicol O-Acetyltransferase; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Expression Regulation; HeLa Cells; Humans; I-kappa B Proteins; NF-kappa B; Paclitaxel; Pancreatic Neoplasms; Promoter Regions, Genetic; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrophosphatases; Transcriptional Activation; Tumor Cells, Cultured; Up-Regulation

2002
Function of nuclear factor kappaB in pancreatic cancer metastasis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:1

    Topics: Animals; Blotting, Northern; Blotting, Western; Boronic Acids; Bortezomib; Enzyme Inhibitors; Genes, Reporter; Humans; Immunohistochemistry; Interleukin-8; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; NF-kappa B; Pancreatic Neoplasms; Phenotype; Pyrazines; Retroviridae; Time Factors; Tumor Cells, Cultured

2003
Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer.
    The Journal of surgical research, 2003, Volume: 113, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Cycle Proteins; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured

2003
The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.
    Molecular cancer therapeutics, 2004, Volume: 3, Issue:1

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Division; Cell Line, Tumor; Docetaxel; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitosis; Neovascularization, Pathologic; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Protease Inhibitors; Pyrazines; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2004
Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2004, Volume: 8, Issue:8

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Line; Deoxycytidine; Enzyme Activation; Gemcitabine; Humans; Immunoblotting; Pancreatic Neoplasms; Protease Inhibitors; Pyrazines; Ribonucleotide Reductases; Tumor Cells, Cultured

2004
Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2005, Volume: 13, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Clinical Trials as Topic; Female; Gastrointestinal Agents; Humans; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Protease Inhibitors; Pyrazines; Statistics, Nonparametric; Treatment Outcome; Weight Loss

2005
Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
    Cancer research, 2005, Mar-15, Volume: 65, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Tumor; Doxorubicin; Drug Synergism; Gene Expression Regulation, Neoplastic; Gene Silencing; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Membrane Glycoproteins; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Quinones; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha

2005
Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib.
    Cancer chemotherapy and pharmacology, 2005, Volume: 56, Issue:1

    Topics: Boronic Acids; Bortezomib; Breast Neoplasms; Cyclin D1; Female; Gene Expression Regulation, Neoplastic; Humans; Male; NF-kappa B; Pancreatic Neoplasms; Prostatic Neoplasms; Protease Inhibitors; Pyrazines; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured

2005
Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells.
    Cancer research, 2005, Dec-15, Volume: 65, Issue:24

    Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Calcium; Caspase Inhibitors; Caspases; Caspases, Initiator; Cycloheximide; eIF-2 Kinase; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Heat-Shock Proteins; Humans; Molecular Chaperones; Oxidative Stress; Pancreas; Pancreatic Neoplasms; Phosphorylation; Protein Biosynthesis; Protein Processing, Post-Translational; Pyrazines; RNA, Small Interfering; Thapsigargin; Transcription Factor CHOP; Ubiquitin

2005
Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis.
    Cancer research, 2005, Dec-15, Volume: 65, Issue:24

    Topics: Animals; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Calcium; Carcinogens; Caspase Inhibitors; Caspases; Cell Line, Tumor; Cisplatin; Cytochromes c; Drug Interactions; Endoplasmic Reticulum; Enzyme Activation; Humans; Immunoblotting; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Pyrazines; RNA, Small Interfering; Thapsigargin; Tumor Stem Cell Assay; Tunicamycin

2005
PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells.
    The Journal of biological chemistry, 2006, Apr-28, Volume: 281, Issue:17

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; bcl-X Protein; Boronic Acids; Bortezomib; Caspase 2; Cathepsin B; Cysteine Endopeptidases; Cytochromes c; Down-Regulation; Enzyme Inhibitors; Humans; Lysosomes; Membrane Proteins; Mitochondrial Membranes; Mitochondrial Proteins; Pancreatic Neoplasms; Permeability; Phosphatidylserines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; RNA, Messenger; Tumor Cells, Cultured

2006
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
    Cancer research, 2006, Apr-01, Volume: 66, Issue:7

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; RNA, Small Interfering; Vorinostat; Xenograft Model Antitumor Assays

2006
Bortezomib in relapsed multiple myeloma complicated by extramedullary plasmacytomas.
    Clinical and laboratory haematology, 2006, Volume: 28, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Humans; Immunohistochemistry; Liver Diseases; Male; Middle Aged; Multiple Myeloma; Pancreatic Neoplasms; Pyrazines; Tomography, X-Ray Computed

2006
Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells.
    Biochemical and biophysical research communications, 2006, Oct-06, Volume: 348, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Boronic Acids; Bortezomib; Caspases; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; NF-kappa B; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines

2006
Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:9

    Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Drug Synergism; Heterocyclic Compounds, 3-Ring; Humans; I-kappa B Proteins; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; NF-KappaB Inhibitor alpha; Pancreatic Neoplasms; Pyrazines; Pyridines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Recombinant Proteins; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays

2006
Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.
    The Journal of surgical research, 2008, Volume: 145, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; NF-kappa B; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Tumor Suppressor Protein p53

2008
Chemopreventive activity of Oltipraz against N-nitrosobis(2-oxopropyl)amine (BOP)-induced ductal pancreatic carcinoma development and effects on survival of Syrian golden hamsters.
    Carcinogenesis, 1995, Volume: 16, Issue:9

    Topics: Animals; Anticarcinogenic Agents; Body Weight; Carcinogens; Carcinoma, Ductal, Breast; Cricetinae; Female; Glutathione Transferase; Immunohistochemistry; Liver; Mesocricetus; Nitrosamines; Pancreas; Pancreatic Neoplasms; Pyrazines; Thiones; Thiophenes; Tumor Suppressor Protein p53

1995
Post-hypoglycaemic hyperketonaemia does not contribute to brain metabolism during insulin-induced hypoglycaemia in humans.
    Diabetologia, 1993, Volume: 36, Issue:11

    Topics: 3-Hydroxybutyric Acid; Adult; Alanine; Brain; Cognition; Diabetes Mellitus, Type 1; Female; Glycerol; Homeostasis; Hormones; Humans; Hydroxybutyrates; Hypoglycemia; Hypolipidemic Agents; Insulin; Insulinoma; Ketone Bodies; Lactates; Lipolysis; Male; Pancreatic Neoplasms; Pyrazines; Reaction Time

1993
A quinolinone derivative, vesnarinone (OPC-8212), significantly inhibits the in vitro and in vivo growth of human pancreatic cancer cell lines.
    Anti-cancer drugs, 1997, Volume: 8, Issue:7

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Cell Survival; Collagen; Drug Combinations; Extracellular Matrix; Humans; Laminin; Mice; Mice, Nude; Neoplasm Invasiveness; Pancreatic Neoplasms; Proteoglycans; Pyrazines; Quinolines; Transplantation, Heterologous; Tumor Cells, Cultured

1997
Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome.
    The Journal of surgical research, 2001, Volume: 100, Issue:1

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Peptide Hydrolases; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Transfection; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2001